Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305496 · ClinicalTrials.gov registry record · Phase 3
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
A Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 818
- Enrollment target
- 20
- Study locations
NCT04305496 is a Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 818 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04305496, a Phase 3 study of Locally Advanced (Inoperable) or Metastatic Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 818 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fulvestrant
- DRUG Capivasertib
Study Locations (20)
California
- Research Site - Orange
- Research Site - San Francisco
- Research Site - Whittier
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
Missouri
- Research Site - Kansas City
- Research Site - St Louis
New York
- Research Site - Lake Success
- Research Site - New York
Tennessee
- Research Site - Chattanooga
- Research Site - Nashville
Arizona
- Research Site - Gilbert
Kansas
- Research Site - Westwood
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 818 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2026-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305496
The ClinicalTrials.gov registry entry for NCT04305496 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 818 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced (Inoperable) or Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04305496 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT04305496 about?
NCT04305496 is a clinical study titled "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer". Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.
What is the current status of trial NCT04305496?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 818 participants. The study started on 2020-04-16. Estimated completion is 2026-06-22.
What conditions does trial NCT04305496 study?
This clinical trial studies the following conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer.
What interventions are being tested in trial NCT04305496?
The interventions under investigation include: Placebo (DRUG), Fulvestrant (DRUG), Capivasertib (DRUG).
Who is sponsoring clinical trial NCT04305496?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305496 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced (Inoperable) or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.